JUN 10, 2020 8:22 PM PDT

A Highly Targeted Cancer Therapeutic

WRITTEN BY: Nouran Amin

A study led by researchers at USC School of Pharmacy discusses a way to engineer drugs that highly target malignant tissues without affecting surrounding healthy tissues. These engineered compounds are known as ‘antibody-drug conjugates’ or ADCs that lead the way to better therapeutics for diverse types of cancer.

Learn more:

"Using our approach, homogenous ADCs could be made through a single-step reaction in less than two hours, much faster and more efficiently than conventional approaches," says the study's Principal Investigator, Yong (Tiger) Zhang, Assistant Professor of Pharmacology and Pharmaceutical Sciences at the USC School of Pharmacy.

As of now, only eight ADC drugs have been approved by the FDA after countless clinical trials evaluating their efficacy and safety in treating leukemia, breast cancer, lung cancer and so much more. The findings were published in Science Advances and describes how ADCs include an antibody that hunts for cancer and that antibody has a chemical linker that is “linking it” to a drug eventually uniting them and eradicating the cancer. This is precisely what makes ADC such an engineered targeted approach.

"Our technology features a designer 'linker' component exclusively recognized by a human enzyme that can rapidly catalyze the conjugation of drug molecules to the antibodies at a defined position," he says. "In addition to its fast rate and high efficiency, our ADC technology offers a new type of linker for connecting the drugs to antibodies. This designer linker ensures stable attachment of the drug and rapid release of the drugs into target cells, making the generated ADCs safer and more efficacious."

Source:  Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
OCT 12, 2020
Cancer
Targeting Energy Production in Cells to Fight Leukemia
OCT 12, 2020
Targeting Energy Production in Cells to Fight Leukemia
Much like how a car needs gasoline to run, cells also need a fuel source. Most human cells in the body use oxidative pho ...
OCT 09, 2020
Technology
Deep Learning Advances Drug Design
OCT 09, 2020
Deep Learning Advances Drug Design
Computational data is advancing all areas of medicine and pharmaceutical drug development is certainly no exception. &nb ...
NOV 08, 2020
Cannabis Sciences
Can Cannabis Treat Epilepsy?
NOV 08, 2020
Can Cannabis Treat Epilepsy?
There has been growing interest in recent years for cannabis to treat central nervous system disorders. And so far, ther ...
NOV 16, 2020
Drug Discovery & Development
A Change of Heart
NOV 16, 2020
A Change of Heart
For a long time cardiovascular issues related to the heart muscular wall have been addressed by therapeutics that target ...
DEC 01, 2020
Drug Discovery & Development
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
DEC 01, 2020
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
Researchers from the Universities of Oxford and Birmingham in the UK have found that otilimab can reduce infla ...
Loading Comments...